Methods and compositions for reduction of side effects of therapeutic treatments

Abstract

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

1 - 121 . (canceled) 
   
   
       122 . A method for reducing drug-induced dyskinesia comprising administering to a human in need of treatment with a drug an amount of a nicotinic receptor agonist sufficient to reduce dyskinesia induced by said drug. 
   
   
       123 . The method of  claim 122  wherein the amount of nicotinic receptor agonist is sufficient to reduce said dyskinesia at least about 30%. 
   
   
       124 . The method of  claim 122  wherein said dyskinesia is induced by a Parkinson's disease treatment. 
   
   
       125 . The method of  claim 124  wherein said Parkinson's disease treatment is a treatment with a dopaminergic agent. 
   
   
       126 . The method of  claim 125  wherein said dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist. 
   
   
       127 . The method of  claim 125  wherein said dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline, ropinorole, apomorphine or a combination thereof. 
   
   
       128 . The method of  claim 127  wherein said dopaminergic agent is levodopa. 
   
   
       129 . The method of  claim 122  wherein said agonist is selected from the group consisting of a simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, an antibody fragment, a vitamin derivative, a carbohydrate and a toxin. 
   
   
       130 . The method of  claim 122  wherein said agonist is selected from the group consisting of nicotine, conotoxinM11, epibatidine, A-85380, cytisine, lobeline, anabasine, SIB-1508Y, SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21 and varenicline. 
   
   
       131 . The method of  claim 130  wherein said agonist is nicotine 
   
   
       132 . The method of  claim 122  wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising at least one a subunit or a nicotinic receptor comprising at least one a subunit and at least one 13 subunit. 
   
   
       133 . The method of  claim 132  wherein said α subunit is selected from the group consisting of α2, α3, α4, α5, α6, α7, α8, α9, and α10 and wherein said β subunit is selected from the group consisting of β2, β3 and β4. 
   
   
       134 . The method of  claim 133  wherein said a subunit is selected from the group consisting of a β3, β4 and β6. 
   
   
       135 . The method of  claim 132  wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising subunits selected from the group consisting of β4β2, α6β2, α4α6β2, α4α5β2, α4α6β2β3, α6β2β3 and α4α2β2. 
   
   
       136 . The method of  claim 132  wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising subunits selected from the group consisting of α4 and α7. 
   
   
       137 . The method of  claim 122  wherein said subject suffers from a condition selected from the group consisting of Parkinson and Alzheimer's disease. 
   
   
       138 . The method of  claim 137  wherein said condition is Parkinson's disease. 
   
   
       139 . The method of  claim 122  wherein said administration comprises a single dose of said nicotinic receptor agonist. 
   
   
       140 . The method of  claim 122  wherein said administration comprises multiple doses of said nicotinic receptor agonist. 
   
   
       141 - 152 . (canceled) 
   
   
       153 . The method of  claim 122  wherein the administering of said nicotine receptor agonist comprises oral administration.